Home
Search
Study Topics
Glossary
|
Study 4 of 17 for search of: | "Agammaglobulinemia" |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00001244 |
This study will explore the cause of immunodeficiency in common variable immunodeficiency (CVI) and other related immunodeficiency syndromes-IgA deficiency, hyper IgM syndrome, thymoma and agammaglobulinemia, hypogammaglobulinemia associated with Epstein-Barr infection, and others-to better focus on how to correct the underlying defect.
Patients with CVI and their family members may participate in this study. Family members must be between the ages of 18 and 85, in good health and weigh at least 110 pounds.
Patients will receive standard medical care for their illness. Procedures may include a medical history and physical examination, routine blood tests, stool examination for infectious agents, lung function tests, chest and sinus X-rays. Treatment may include administration of immune serum globulin, antibiotics for infections, and anti-inflammatory drugs, if needed. In addition, patients may undergo the following:
Some of the blood collected may be used for genetic tests. Some blood and tissue samples may be stored for future research-labeled with a code, such as a number, that only the study team can link to the patient.
Participating family members will provide a medical history, and their pulse, blood pressure and temperature will be taken. They will have 10 to 120 ml (1/3 to 4 ounces) of blood drawn from a vein in the arm. Blood samples may be taken on repeated occasions as long as the relative remains in the study. The blood will be used for research that may involve development of diagnostic tests for CVI, evaluation of the structure and function of normal blood cells for comparison with those of patients with CVI, and studies to try to determine possible genetic factors involved in susceptibility to CVI.
Condition |
---|
Agammaglobulinemia Common Variable Immunodeficiency Immunologic Deficiency Syndrome |
Study Type: | Observational |
Official Title: | Studies of Immune Regulation in Patients With Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes |
Estimated Enrollment: | 250 |
Study Start Date: | September 1989 |
The purpose of this protocol is to carry out laboratory studies concerning the
immunopathogenesis of Common Variable Immunodeficiency (CVI) and related primary
humoral immunodeficiency diseases. Additionally, we aim to document and track the
progression of known complications of this primary immunodeficiencv. Complications
associated with CVID include recurrent respiratory, and gastrointestinal bacterial infections, pulmonary insufficiency, lymphoid malignancy, and various autoimmune manifestations.
Patients with CVI and related B Cell immunodeficiencies will be enrolled into this
natural history study. Protocol procedures will include baseline measurements of and changes in lab and radiographic studies. Changes in the patients' clinical state will be measured to determine the precursors of disease complications. This may lead to developments in improving preventive measures and novel treatment options for this population.
Ages Eligible for Study: | 2 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Must have a verifiable diagnosis of common variable immune deficiency as defined by a decrease both in IgG and at least one other Ig isotype to below two standard deviations of normal control levels.
Or
B cell immunodeficiencies related to CVI (defined as selective IgA deficiency, hyper IgM syndrome, thymoma and agammaglobulinemia, and hypogammaglobulinemia associated with Epstein-Barr virus infection) or hypogammaglobulemia associated with other related immunodeficiencies.
Must be 2 years old or greater.
Patients with repeated infections and suspected of having an immunodeficiency syndrome.
Patients must have a primary medical care provider as a criterion for inclusion into this study.
EXCLUSION CRITERIA:
Presence of other medical illnesses that would preclude individuals from undergoing routine diagnostic testing or testing for immunologic features of immunodeficiency.
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Study ID Numbers: | 890158, 89-I-0158 |
Study First Received: | November 3, 1999 |
Last Updated: | October 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00001244 |
Health Authority: | United States: Federal Government |
Agammaglobulinemia Primary Immune Deficiency Immune Response |
Lymphatic Diseases Agammaglobulinemia Common variable immunodeficiency Hematologic Diseases |
Blood Protein Disorders Lymphoproliferative Disorders Common Variable Immunodeficiency Immunologic Deficiency Syndromes |
Pathologic Processes Disease Immune System Diseases Syndrome |